Table 2.
Associations of baseline fibroblast growth factor 23 with prevalent anemia
| Number of Patients, Total N | Per 1 SD ln FGF23 | FGF23 Quartiles, RU/ml | P Value for Trend | |||
|---|---|---|---|---|---|---|
| Quartile 1: ≤96.0, N=969 | Quartile 2: 96.1–145.6, N=966 | Quartile 3: 145.7–239.2, N=967 | Quartile 4: ≥239.3, N=967 | |||
| Prevalence | ||||||
| 1872 | 48 | 26 | 46 | 55 | 67 | |
| 3869 | ||||||
| Unadjusted odds ratio (95% CI) | ||||||
| 1872 | 1.88 (1.75 to 2.03) | Reference | 2.37 (1.96 to 2.87) | 3.34 (2.76 to 4.04) | 5.58 (4.59 to 6.79) | <0.001 |
| 3869 | ||||||
| Plus demographic factorsa | ||||||
| 1872 | 1.85 (1.71 to 2.00) | Reference | 2.31 (1.90 to 2.82) | 3.30 (2.71 to 4.02) | 5.34 (4.36 to 6.55) | <0.001 |
| 3869 | ||||||
| Plus cardiovascular risk factorsb | ||||||
| 1871 | 1.75 (1.61 to 1.90) | Reference | 2.14 (1.74 to 2.62) | 2.77 (2.25 to 3.41) | 4.65 (3.73 to 5.79) | <0.001 |
| 3866 | ||||||
| Plus CKD-specific factorsc | ||||||
| 1871 | 1.41 (1.30 to 1.54) | Reference | 1.78 (1.44 to 2.20) | 1.85 (1.48 to 2.30) | 2.62 (2.06 to 3.34) | <0.001 |
| 3866 | ||||||
| Plus markers of mineral metabolismd | ||||||
| 1817 | 1.39 (1.26 to 1.52) | Reference | 1.76 (1.42 to 2.18) | 1.80 (1.43 to 2.26) | 2.52 (1.95 to 3.24) | <0.001 |
| 3750 | ||||||
Continuous results are reported as odds ratios per 1-SD increase in ln-transformed FGF23. N, number; ln, natural log; FGF23, fibroblast growth factor 23; 95% CI, 95% confidence interval.
a
Adjusts for age, sex, race, and ethnicity.
b
Adjusts for factors in model 1 as well as cardiovascular disease, systolic BP, diabetes, smoking, and C-reactive protein.
c
Adjusts for factors in model 2 as well as eGFR and urinary albumin-to-creatinine ratio.
d
Full multivariable model: adjusts for factors in model 3 as well as calcium, phosphate, and parathyroid hormone.